Aktienanalyse zu Labcorp Holdings Inc (LH)LHLabcorp Holdings Inc

Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Laboratory Corporation of America Holdings (LH) is a good buy right now due to its current price of $317.95, which is below the average analyst price target of $365 to $380, indicating significant upside potential. The stock has shown a year-to-date change of +26.34%, reflecting strong performance. However, the upcoming CMS rate cuts pose a risk, potentially reducing revenue by up to 1.2% if fully implemented, which is a key factor to monitor.

19 analysts cover LH: 13 rate it Buy, 6 Hold and 0 Sell. The average price target is 304.45.